Kornimate/medical-research-clean huggingface dataset:
acupuncture for prophylaxis of vestibular migraine

Conditions: Vestibular Migraine

Summary: with its high incidence rate and low diagnosis rate, vestibular migraine (vm) can seriously affect patients' quality of life. current treatment of vm mainly contain rescue treatment and prophylaxis, both of which are often pharmacological-based therapies and bring a series of unavoidable side effects, which leads to poor compliance of patients. moreover, frequent vm attacks can seriously affect patients' daily life and work. therefore, prophylaxis treatment is of great significance for vm patients. as a non-pharmarceutical therapy, acupuncture is widely used for a wide range of migrainous and emotional disorders. thus, it might be an alternative treatment for vm, but current evidence remains inconclusive. the aim of this randomized controlled trial is to investigate the prophylactic efficacy and safety of acupuncture therapy in patients with vm.

this randomized controlled trial will enroll patients with vestibular migraine from the first affiliated hospital of jiaxing university. all participants will be randomly assigned to two groups. participants will receive acupuncture in the treatment group, while participants in the control group will be treated by venlafaxine. all treatments will be given for 8 weeks. the primary outcome measures are change in vertigo/migraine days and vertigo/migraine attacks, vertigo severity, and migraine intensity per 4 weeks from baseline. the secondary outcome measures are change in dosage of rescue medication, anxiety level，depression level，and quality of life per 4 weeks from baseline.

Eligibility criteria:
inclusion criteria: 1. patients with age 18 to 80 , male or female; 2. patients meet the criteria proposed by the collaboration of barany society and the international headache society in 2012; 3. vertigo/migraine attacks at least 3 times per month in the last 3 months; or vertigo/migraine days are at least 4 days per month; 4. patients have unsatisfactory response to rescue treatments and seek for preventive treatments; 5. patients can fully understand the study protocol and agree to sign written informed consent forms. exclusion criteria: 1. patients'vertigo and headache are caused by other diseases, such as vestibular neuritis, meniere disease, tension headache, and other cerebrovascular diseases. 2. patients have prophylactic headache treatment with drugs in the past 3 months. 3. patients are receiving adjunctive therapy that is not widely accepted for treating vm, such as chinese herbs. 4. patients have severe complications in cardiovascular, cerebrovascular, liver, kidney, hematopoietic and other systems that are not controlled significantly; 5. pregnant and lactating female patients; 6. patients have mental illness that affects cognitive function.

Keywords: vestibular migraine randomized controlled trial acupuncture
a study of abemaciclib in participants with cancer that is advanced or has spread to another part(s) of the body

Conditions: Neoplasm Metastasis

Summary: this study is known as a "drug interaction study" and is being done to see how abemaciclib may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin, dextromethorphan, and midazolam) when taken in combination with abemaciclib. each participant will complete screening and four study periods in a fixed sequence, with the option to continue to receive abemaciclib in a safety extension phase. all participants will complete a safety follow-up.


Eligibility criteria:
inclusion criteria: * have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic * have adequate organ function * have a performance status of ≤2 on the eastern cooperative oncology group (ecog) scale * have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, cancer-related hormone therapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug and have recovered from the acute effects of therapy(treatment related toxicity resolved to baseline), except for residual alopecia exclusion criteria: * require treatment with inducers or inhibitors of cytochrome p450 (cyp)1a2, cyp2c9, cyp2d6, and cyp3a within 14 days before the first dose of study drug through the end of period 2 * history or presence of significant bleeding disorders * have known active uncontrolled or symptomatic cns metastases * have a primary liver tumor * have lymphoma or leukemia
the reliability and validity of the functional reach test in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: loss of limits of stability ability is one of the major components of balance dysfunction in ms. the functional reach test is quick and clinically available tool for assessing limits of stability but reliability and validity of this test has not yet been systematically examined in people with multiple sclerosis.the aim of the study is to investigate reliability and validity of the functional reach test in patients with multiple sclerosis.

at baseline, the functional reach test, limits of stability test by using biodex balance system, berg balance scale, four step square test, and timed up and go test was applied to the patients with multiple sclerosis. the functional reach test was repeated after seven days from the first application to evaluate its reliability.

Eligibility criteria:
inclusion criteria: * at least 18 years, * neurologist-diagnosed multiple sclerosis, * expanded disability status scale (edss) score \< 7, * able to walk 20 m with or without aids, * no ms exacerbation within the last 2 months, * use of stable medication in the last 2 months. exclusion criteria: * other neurologic disorder, * pregnancy, * orthopedic problems affecting gait and stance, * visual, auditory, orientational problems that could affect study results, * cardiovascular, pulmonary, and humoral disease.

Keywords: multiple sclerosis functional reach test reliability validity
an open-label safety study of dic075v (intravenous diclofenac sodium) in patients with acute post-operative pain

Conditions: Pain, Postoperative

Summary: this is an open-label, multiple-dose, safety study of dic075v in patients with acute post-operative pain following abdominal or orthopedic surgery.

this is an open-label, multiple-dose, multiple-day, single-arm safety study of repeat-doses of dic075v in patients with acute post-operative pain following abdominal (i.e., non-laparoscopic abdominal surgeries) or orthopedic (e.g., hip or knee joint replacement) surgery. eligible patients will receive dic075v iv bolus q6 hours. safety assessments will be collected at baseline (immediately prior to starting dic075v therapy) and at study discharge or early termination.

Eligibility criteria:
inclusion criteria: * abdominal ( non-laparoscopic abdominal surgeries) or orthopedic ( hip or knee joint replacement) surgery or other surgeries requiring multiple doses of parenterally administered nsaids over multiple days * expected stay \> 48 hrs exclusion criteria: * bilirubin \> 2.5 mg/dl * prothrombin time is \> 20% above the upper limit of normal * serum creatinine is \> 1.9 mg/dl at screening. * known allergy or hypersensitivity to diclofenac, other nsaids,

Keywords: safety diclofenac pain, postoperative
efficacy of memantine add-on in the treatment of bipolar disorder (type i) nonresponders or partial responders patients

Conditions: Bipolar Disorder

Summary: the main goal of this study is evaluate the efficacy of memantine association on the treatment with a previous combination of two drugs, including quetiapine with lithium or quetiapine with aripiprazole in young patients with bipolar disorder type 1 non-responders or partial responders to that combination of drugs and evaluate the impact of this association at the cognitive functioning of the patients.

current evidence suggests that deregulation of brain glutamatergic neurotransmission is involved in the pathophysiology of bipolar disorder and that drugs that intervene in this transmission may be therapeutic weapons in addressing the symptoms and cognitive deficits of this pathology. among these drugs, particularly memantine is a strong candidate in view of their efficacy in antagonizing n-methyl-d-aspartate (nmda) receptors, and their good safety and tolerability profile. the principal aim of this study is to evaluate the efficacy of memantine association with treatment with a combination of two drugs, including quetiapine with lithium and quetiapine with aripiprazole in young patients with bipolar disorder type 1 non-responders or partial responders and evaluate the impact of this association cognitive functioning of patients. an experimental study, randomized, double-blind, bipolar patients with type 1, of both sexes, aged 18 to 40, ambulatory or hospitalized, at any stage of the disease, seeking treatment in the mood disorders program (gruda) of institute os psychiatry (ipq) of sao paulo university (fmusp). patients will come from ariqueli project (missio, g. et al, 2013 submitted trial registration - clinicaltrials.gov identifier:. nct01710163). the study will be conducted in two stages: i - initial administration of memantine or placebo for 8 weeks; ii - maintenance administration for more 4 months.

Eligibility criteria:
* inclusion criteria: 1) partial responders or non-responders (ham-d score \> 7 points and/or ymrs \> 9 points) in the ariqueli study (after quetiapine + lithium or quetiapine + aripiprazole combination). * exclusion criteria: 1. patients with schizophrenia, schizoaffective disorder or mental retardation (intellectual quotient total less than 90); 2. patients with severe, unstable diseases, including kidney disease, gastroenterology, respiratory, cardiovascular, endocrine, neurological, immunological or haematological; 3. hypo or hyperthyroidism uncorrected; 4. angle-closure glaucoma; 5. changes in blood coagulation or use of regular anticoagulants; 6. patients with serious risk of suicide (according to clinical criteria and / or score\> = 4 in the ham-d item suicide) may participate in the study only in inpatients;

Keywords: bipolar disorder memantine lithium aripiprazole quetiapine central nervous system agents therapeutic uses pharmacologic actions psychotropic drugs cognitive effect of drugs
evaluating an online wellness intervention for indian college students

Conditions: Depressive Symptoms; Anxiety; Happiness

Summary: we are evaluating the effects of an online single-session mental health intervention (the common elements toolbox; comet). to evaluate comet, we are conducting a randomized controlled trial with indian college students. students will be randomized to the comet condition or to a wait-list control condition. primary outcome measures (depressive symptoms, anxiety symptoms, and subjective well-being) will be measures at two weeks post-intervention, four weeks post-intervention, and twelve weeks post-intervention. we will evaluate comet as a universal intervention (using the full sample) and as a targeted intervention (analyzing those who reported elevated depressive symptoms or anxiety symptoms at baseline).


Eligibility criteria:
inclusion criteria: at least 18 years old and a student at a participating university in india.
shared decision making and how it impacts the patient understanding

Conditions: Knee Osteoarthritis

Summary: shared decision making (sdm) supports patient centered care and improves patient outcomes and satisfaction. movement is life (mil) created an innovative sdm tool to provide a personalized framework for discussion of the projected impact to patients of their decisions regarding treatment options for knee osteoarthritis. 1. did use of the mil sdm tool for knee osteoarthritis result in an increased level of self-reported physical activity at one month in african american and hispanic women? 2. did use of the mil smd tool increase subject likeliness to recommend the physician? 3. what is the qualitative feedback from subjects on ease of use of the mil sdm tool?


Eligibility criteria:
inclusion criteria: * - aged 45 to 64 years * mild to moderate knee pain consistent with a diagnosis of osteoarthritis by the clinician * self-identified as african american and/or hispanic * at least one of the following comorbidities: 1. obesity (bmi ≥ 30), 2. hypertension (icd10 codes below) 3. diabetes (icd10 codes below) exclusion criteria: * - known inflammatory arthritis (lupus, sjogrens, rheumatoid arthritis) * prior total knee replacement * recommended total knee replacement * acute knee trauma

Keywords: shared decision making
validity and reliability of the telephone interview form for stroke outcome evaluation

Conditions: Stroke

Summary: the investigators combined the mrs questionnaire and bi questionnaire and then developed a telephone interview form as a simple questionnaire with internal rules. the main purpose of this study is to evaluate the validity and reliability of the telephone interview form when compared with face-to-face assessment in clinically stable patients with stroke.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of ischemic or hemorrhagic stroke. * the course of 1 to 12 months. * patient or procuratorial caregiver has a good understanding so as to answer rater's telephone interview. * patient or legally authorized representative has signed informed consent. exclusion criteria: * patients with psychological or mental disorders. * patients suffer from other so severe diseases that they can't complete the follow-up.

Keywords: stroke outcomes telephone interview modified rankin scale questionnaire barthel index questionnaire validity study reliability study
neutrophil gelatinase-associated lipocalin as a new biomarker to detect acute kidney injury in postoperative cardiac surgery

Conditions: Cardiac Surgery

Summary: observational study aimed to test the ability of neutrophil gelatinase-associated lipocalin (ngal) concentration in blood and urine to predict and diagnose early acute renal failure (arf) in patients after cardiac surgery with/without cardiopulmonary bypass (cpb).


Eligibility criteria:
inclusion criteria: * men or women over 18 years proposed for cardiac surgery with / without cpb. * accepting to participate in the study, with informed consent signed by the patient, guardian or family member. exclusion criteria: * patients \< 18 years. * patients do not agree to participate in the study.
effects of a multi-ingredient pre-workout supplement on body composition, performance, muscular properties, and wellbeing in adults.

Conditions: Protein Deficiency; Training Group, Sensitivity; Fatigue; Muscular Atrophy; Psychological

Summary: the investigation will be conducted as a double blinded, randomized, parallel between treatment conditions comparison design with two different groups ingesting a different supplement each one.

following inclusion, familiarization and baseline assessments, the participants will be randomly allocated to receive either a multi-ingredient, pre-workout supplement (prew) or maltodextrin (cho). thereafter, the participants will follow a 6-weeks resistance training mesocycle, involving three resistance training sessions (monday, wednesday and friday) per week (18 sessions in total). before and after the 6 weeks of intervention, the following assessments will be performed: (i) body composition (fat mass and fat-free mass) via air displacement plethysmography (bodpod); (ii) muscle contractile properties on vastus medialis and anterior deltoids (via tensiomyography; (iii) muscle structure of the vastus lateralis of the quadriceps and the elbow flexors of dominant extremities via ultrasound; (iv) maximal isometric strength (isometric mid-thigh pull); (v) upper and lower body muscular power (medicine ball throw and vertical jump), (vi) upper and lower muscular endurance (30-seconds sit-to-stand and 30-seconds 16rm bench press), (vii) immune system (via hemocue wbc diff system). the supplements will be ingested 15 min before each training session. energy feeling questionnaire will be filled immediately before warming up. in addition, rate of perceived exertion to training will be assessed 15 min after the completion of all workouts.

Eligibility criteria:
inclusion criteria: * healthy (no injuries, illnesses or medication intake). * between 45 and 65 years old. * active and familiarised with resistance training. exclusion criteria: * unhealthy (illnesses or medication intake) or injured. * untrained. * young (\ 65 y.o.).

Keywords: fatigue supplement protein resistance training pre-workout strength rate of perceived exertion muscle
treatment of patients with periorbital hyperpigmentation

Conditions: Periorbital Hypermelanosis

Summary: periorbital hyperpigmentation (poh) is a common condition in dermatology practice. periorbital hyperpigmentation is defined as bilateral, round, homogeneous pigmented macules.the etiology of poh is multifactorial including genetic and enviromental factors. many treatment options are avaiblabe with variable efficacy and safety in different patients. therefore, the investigator's study aims to evaluate the efficacy and safety of combined microneedling with topical glutathione versus carboxy therapy in treatment of patients with periorbital hyperpigmentation.

periorbital hyperpigmentation (poh) is a common skin condition which has a great negative effect on the patient quality of life. many factors contribute in the pathogensis of poh which lead to developement of several treatment options with no treatment option has a great sucess in improving the poh and patient quality of life. our current study tries to explore the efficacy and safety between 2 treatment methods in a split face study. microneedling is a process of making small punctres into the skin through small needles by device which is called a dermapen. this microneedling method is beleived to be associated with improving the skin quality through increased collagen. this microneedling will be followed by topical application of glutathione which is a commong antioxidant with whitening effects. carboxy therapy is a new emerging treatment option in many dermatological diseases. it will be used in poh patients as it will be able to increase blood flow in periorbital area and improve the skin qulaity.

Eligibility criteria:
inclusion criteria: * patients with periorbital hyperpigmentation exclusion criteria: * pregnancy and lactation . * allergy, hypersensitivity to the formulations to be used in the study. * any other cutaneous or systemic disease. * patient who had taken any other treatment (laser, dermabrasion) on the affected region performed less than 6 months prior to the beginning of the study.

Keywords: periorbital hypermelanosis carboxy therapy microneedling topical glutathione
extending sleep to reverse metabolic syndrome in middle-aged adults: acceptability and feasibility of a sleep intervention

Conditions: Sleep; Metabolic Syndrome

Summary: this pilot study will test acceptability and feasibility of a sleep extension intervention in community dwelling, short sleeping, racially/ethnically diverse middle aged adults with metabolic syndrome (mets). baseline sleep habits will be assessed and used to guide individualized strategies to extend sleep. a 1-group pre-test, post-test study design will test the efficacy of this 18 week study (2 weeks of baseline data collection, 1 week of study intervention planning, 12 weeks of sleep intervention planning, 12 weeks of sleep intervention delivery, final follow up 3 weeks after last day of the 12 week intervention) on sleep duration, mets factors (waist circumference, blood pressure, fasting glucose, trigycerides, hdl-c), mets risk behaviors (poor affective well-being, fatigue) and self regulation. socio-ecological barriers and facilitators to the intervention will be identified using a quantitative and qualitative approach.


Eligibility criteria:
inclusion criteria: * greater than or equal to 40 years of age and less than or equal to 60 years of age. * objectively confirmed mets defined by three or more of the following: 1. waist circumference greater than 120cm (men) or 88cm (women), 2. blood pressure greater than or equal to 135 mmhg systolic or greater than or equal to 85 mmhg diastolic or antihypertensive medication use, 3. fasting glucose greater than or equal to 110 mg/dl or insulin or oral hypoglycemic medication use, 4. serum triglycerides greater than or equal to 150mg/dl or hypertriglyceridia medication use, 5. hdl-c less than 40mg/dl (women) or less than 50 mg/dl (men) or medication use for low hdl-c1. mets was selected because individuals with mets are at high risk for multiple chronic conditions35. * no obstructive sleep apnea. * accelerometry confirmed short sleep (average work day sleep less than or equal to 6 hours/night). * english speaking. exclusion criteria: * pregnancy/lactation * current chemotherapy treatments * alcohol abuse/dependence * night shift or shift work (previous 2 months) * trans-meridian travel (previous 4 weeks), * planned shift work or trans-meridian travel during intervention period * insomnia * moderate-severe or severe depression * sleep-promoting medications * habitual napping, defined as 2 naps per day or \> 90 minutes of napping on 3 or more days of the week.
spanish percutaneous aortic intervention registry (spain registry)

Conditions: Aorta Aneurysm; Aorta Dissection; Aorta Stenosis; Aortic Coarctation; Aortic Rupture; Aortic Valve Disease; Aortic Valve Stenosis

Summary: multicentre prospective registry including consecutive patients undergoing percutaneous endovascular aneurysm repair (pevar), percutaneous endovascular thoracic aneurysm repair (ptevar) or transcatheter aortic valve implantation (tavi) in which variables related to the percutaneous access closure for implanting devices at aorta level will be collected and analyzed. the follow-up period will be 30 days after the procedure. the duration of the recruitment period will be one year. all data will be collected telematically and incorporated into a database for subsequent statistical analysis. there will be 2 points for data interim analysis at 6 and 12 months after initiation of the study.


Eligibility criteria:
inclusion criteria: * men and women over 18 years old * signed informed consent * endovascular procedures on the aorta to any level, performed by percutaneous access and requiring the use of devices ≥ 10f * femoral access suitable for percutaneous treatment in the opinion of the surgeon exclusion criteria: * need for surgical repair of the femoral artery (stenosis aneurysmal) * initial indication of percutaneous closure with another device different from the perclose proglide * active infection of the puncture site * condition that prevents complete the 30 days follow up

Keywords: percutaneous access